NEW YORK – After announcing new clinical data last week on the performance of its next-generation pancreatic cancer test PancreaSure, Swedish diagnostic firm Immunovia is preparing to launch the assay in the second half of 2025.
Already registered? LoginLogin
Get the full story with 360Dx Premium
Only $95 for the first 90 days
Benefits:
Full site access
Interest-based email alerts
Access to archives
Premium Access - Trial Offer
$95.00 for 3 month
Benefits:
Full site access
Interest-based email alerts
Access to archives
Already registered? LoginLogin
